- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00262652
Safety and Efficacy Study of the Use of Sodium Pyruvate Bronchodilation in Asthmatics
Sodium Pyruvate Bronchodilation in Asthmatics
Study Overview
Detailed Description
Sodium Pyruvate, an intermediate metabolite, has been investigated as a therapeutic agent to reduce reactive oxygen species in the lung. Evaluation of FEV1 as a safety parameter and sequela of reactive oxygen species reduction identified inhaled Sodium Pyruvate as a potential bronchodilator.
A number of lung diseases are typically characterized by marked inflammation at the site of the lung injury. This inflammatory process leads to further destruction of surrounding healthy lung tissue, and a continuation and expansion of the sites of inflammation. This inflammatory process results in the production of reactive oxygen species, including superoxide anions and hydrogen peroxide, at the site of inflammation.
Nitric oxide is a known bronchodilator, as well as a vasodilator. It has been used successfully used to treat patients with various pulmonary disorders. 1 When endogenous nitric oxide is exposed to oxygen radicals, however, it is converted to the toxic oxidant nitrogen dioxide, and its bronchodilating effect is mitigated. Conversely, nitrogen dioxide is a known deep lung irritant. Its adverse consequences include the following: pulmonary inflammation; reduced levels of lung antioxidants 2; impairment of respiratory defense mechanisms leading to increased susceptibility to respiratory pathogens 3 and increased incidence and severity of respiratory infections; reduced lung function, and increased asthma and COPD symptoms.
Reactive oxygen species, especially superoxide anions, are known to compromise lung function by increasing bronchoconstriction. As a result of the increasing inflammation and the production of reactive oxygen species, and the decrease in nitric oxide that is believed to occur with the interstitial lung diseases, healthy tissue is damaged and lung function is compromised.
Based on our present understanding of the disease process involved with these lung diseases, it appears that an intervention in the inflammatory process that would result in a reduction in reactive oxygen species and a subsequent increase in nitric oxide could be an effective way to intervene in the disease process. This intervention would prevent the further spread of inflammation and lung damage caused by the production of reactive oxygen species, such as superoxide anions and hydrogen peroxide, and increase lung function by increasing bronchodilation.
Sodium pyruvate is a reactive oxygen species antagonist that has been shown to neutralize oxygen radicals, specifically lowering the overproduction of superoxide anions, regulate the production and level of other inflammatory mediators, and increase the synthesis of nitric oxide. 4 Sodium pyruvate also increases cellular levels of glutathione, a major cellular antioxidant, which is reduced dramatically in antigen-induced lung disease patients. 5
In pilot studies in mild asthmatic subjects, it was demonstrated that inhalation of low doses (0.5 mM) of nebulized sodium pyruvate decreased expired hydrogen peroxide by 30% at four hours compared to inhalation of a nebulized saline control. These subjects also experienced increased pulmonary function as determined by FEV1 (+12.8%) and PEF (+34.5%) measurements after four hours (referenced in Cellular Sciences IND #50,089). It is theorized that the reactive oxygen species antagonist properties of sodium pyruvate reduced the production of oxygen radicals, including hydrogen peroxide, and increased the levels of nitric oxide. Together, this led to reduced inflammation and lung damage, and increased lung function through improved bronchodilation.
In summary, it is believed that inhalation of sodium pyruvate will reduce the lung damage resulting from the increase in reactive oxygen species associated with the inflammation component of the disease, and will enhances the availability of nitric oxide to produce bronchodilation by enhancing its synthesis and protecting it from destruction by reactive oxygen species.
Experimental Clinical Protocol Hypothesis: Sodium Pyruvate delivered by nebulization to the lungs produces bronchodilation in asthmatics as measured by FEV1
Intent: Provide support for further drug development of nebulized Sodium Pyruvate as a therapeutic agent in asthma
Design Randomized, double-blind, placebo-controlled cross-over study of 52 completed subjects
Treatment 1: 0.5 mM sodium pyruvate in 0.9% saline solution, (5ml) (Cellular Sciences, CA) nebulized via a Pari LC Plus(R) reusable nebulizer powered by a ProNeb(R) compressor (Midlothian, VA) Treatment 2: Saline 0.9%, (5ml) (Baxter) nebulized using the same nebulizer system as above A randomization algorithm using random permuted blocks (4-8 subjects) will be used to generate treatment order assignments. An unblinded statistician will generate this list of treatment order assignments.
Patient Recruitment and Selection The large cohort of potential subjects who have previously participated in asthma studies through our clinical research laboratory will be apprised of the study. Patients attending the UCLA Asthma and Cough Center will also be informed of the study. Advertisements will be sent by regular mail and by e-mail to physicians participating in the UCLA Healthcare System and to local pulmonologists practicing throughout the Los Angeles area. Local Allergists who collaborate with us in common clinical trial protocols will be informed of the study by personalized letter and e-mail. Advertisements will be placed in the classified and/or health sections of local newspapers. A description of the study will be posted on internet sites featuring clinical research trials.
Subjects will be recruited until a total of 52 complete the study. Assuming a 5% drop-out and non-compliance rate, we expect a total of 55 subjects recruited Patient Eligibility Criteria
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- David Geffen School of Medicine, UCLA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A physician diagnosis of asthma
- Age years old
- Symptoms consistent with asthma for at least 6 months
Current asthma medications: Short-acting inhaled beta agonists as needed for control of asthma symptoms with or without a low to medium dose of an ICS, as defined in the table below and if on a ICS may also be on a long-acting beta agonist provided it is withheld for 24 hours prior to the testing days.
Inhaled Corticosteroid Dose less than or equal to:
Beclomethasone-HFA 480 µg/day Budesonide-DPI 1000 µg/day Flunisolide 2000 µg/day Fluticasone 500 µg/day Triamcinolone 2000 µg/day
- FEV1 at screening 50-80% predicted (Hankinson6)
- Reversibility with albuterol of 12% and 200 ml FEV1FEV1 at 30 minutes.
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
ANCOVA using multiple measures evaluating FEV1% predicted at 5, 15, 30, 60, 120 and 240 minutes between saline and Sodium Pyruvate,and at 5, 15 and 30 minutes between albuterol and Sodium Pyruvate with the visit baseline FEV1% predicted as covariate.
Time Frame: Four Hour Testing
|
Four Hour Testing
|
No other primary outcome variable
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Donald Tashkin, M.D., University of California, Los Angeles; Center for the Health Sciences
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSI-UCLA-ASTHMA-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Moderate Asthma
-
KoBioLabsNovotech (Australia) Pty LimitedCompletedModerate to Severe AsthmaAustralia
-
Societa Italiana di PneumologiaSocietà Italiana di Allergologia, Asma e Immunologia ClinicaRecruiting
-
SamA Pharmaceutical Co., LtdCompleted
-
Eurofarma Laboratorios S.A.Not yet recruiting
-
Regeneron PharmaceuticalsSanofiCompletedAsthma | Moderate AsthmaUnited Kingdom
-
Koneksa HealthCompleted
-
Guangzhou Institute of Respiratory DiseaseUnknown
-
MedImmune LLCTerminatedModerate AsthmaUnited Kingdom
-
Lu Yuan LeeNational Institute of Allergy and Infectious Diseases (NIAID)WithdrawnPulmonary Atelectasis | Severe Persistent Asthma | Moderate Persistent Asthma | Nodule Solitary PulmonaryUnited States
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)RecruitingModerate to Severe AsthmaUnited States
Clinical Trials on sodium pyruvate
-
University of MinnesotaCellular Sciences, inc.TerminatedCystic FibrosisUnited States
-
Cellular Sciences, inc.Missouri State University; Dynamic DNA Labs; Trinity Health Care; Family First...Completed
-
EmphycorpCellular Sciences, inc.Completed
-
EmphycorpCellular Sciences, inc.Completed
-
Cellular Sciences, inc.Missouri State University; Dynamic DNA Labs; Trinity Health Care; Family First...Completed
-
University of Texas Southwestern Medical CenterEnrolling by invitationTraumatic Brain InjuryUnited States
-
Chang Gung Memorial HospitalMinistry of Science and Technology, TaiwanRecruiting
-
Cellular Sciences, inc.Family First Medical Research CenterRecruiting
-
Chang Gung Memorial HospitalNational Science and Technology CouncilNot yet recruitingCervical Cancer | Gynecologic Cancer | Ovarian Cancer | Endometrial CancerTaiwan
-
Javier Villaneuva-Meyer, MDNational Institute for Biomedical Imaging and Bioengineering (NIBIB); General...RecruitingMeningiomaUnited States